tiprankstipranks
Advertisement
Advertisement

ANTX Stock Latest News

Analyst Sees Material Upside for AN2 Therapeutics as Epetraborole Targets Underserved Polycythemia Vera Market
RatingsAnalyst Sees Material Upside for AN2 Therapeutics as Epetraborole Targets Underserved Polycythemia Vera Market
3d ago
ANTX
AN2 Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
AN2 Therapeutics initiated with a Buy at Guggenheim
3d ago
ANTX
AN2 Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
AN2 Therapeutics initiated with a Buy at Guggenheim
3d ago
ANTX
One new option listing on July 17th
PremiumThe Fly
One new option listing on July 17th
6d ago
ANTX
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
PremiumCompany Announcements
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
1M ago
8K
ANTX
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
PremiumCompany AnnouncementsAN2 Therapeutics Advances Chagas Candidate After Positive Trials
2M ago
8K
ANTX
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
Premium
The Fly
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
2M ago
ANTX
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
Premium
The Fly
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
2M ago
ANTX
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
PremiumThe Fly
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
2M ago
ANTX
AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
2M ago
ANTX
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
PremiumCompany Announcements
AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
3M ago
ANTX
AN2 Therapeutics Launches New $80 Million ATM Program
PremiumCompany Announcements
AN2 Therapeutics Launches New $80 Million ATM Program
3M ago
8K
ANTX
AN2 Therapeutics files $300M mixed securities shelf
PremiumThe FlyAN2 Therapeutics files $300M mixed securities shelf
3M ago
ANTX
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
Premium
The Fly
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
4M ago
ANTX
AN2 Therapeutics Reprices Stock Options to Enhance Retention
Premium
Company Announcements
AN2 Therapeutics Reprices Stock Options to Enhance Retention
4M ago
8K
ANTX
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
4M ago
ANTX
AN2 Therapeutics Announces $40 Million Private Placement Financing
PremiumCompany Announcements
AN2 Therapeutics Announces $40 Million Private Placement Financing
4M ago
8K
ANTX
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
PremiumThe Fly
AN2 Therapeutics to advance oral Epetraborole into Phase 2 study
5M ago
ANTX
AN2 Therapeutics adjusts leadership roles and executive compensation
PremiumCompany Announcements
AN2 Therapeutics adjusts leadership roles and executive compensation
6M ago
8K
ANTX
AN2 Therapeutics announces FDA clearance of OSHU IND application
PremiumThe FlyAN2 Therapeutics announces FDA clearance of OSHU IND application
6M ago
ANTX
AN2 Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
AN2 Therapeutics Reports Q3 2025 Financial Results
8M ago
ANTX
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
Premium
The Fly
AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)
8M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >